| Item Type | Name |
|
Concept
|
Combined Modality Therapy
|
|
Concept
|
Drug Therapy
|
|
Concept
|
Drug Therapy, Combination
|
|
Concept
|
Salvage Therapy
|
|
Concept
|
Treatment Outcome
|
|
Concept
|
Therapeutic Human Experimentation
|
|
Concept
|
Hormone Replacement Therapy
|
|
Concept
|
Therapeutic Equivalency
|
|
Concept
|
Molecular Targeted Therapy
|
|
Concept
|
Neoadjuvant Therapy
|
|
Academic Article
|
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
|
|
Academic Article
|
Adjuvant therapy of colon cancer.
|
|
Academic Article
|
Adjuvant therapy for colorectal cancer.
|
|
Academic Article
|
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel.
|
|
Academic Article
|
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
|
|
Academic Article
|
An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma.
|
|
Academic Article
|
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma.
|
|
Academic Article
|
Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.
|
|
Academic Article
|
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
|
|
Academic Article
|
High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.
|
|
Academic Article
|
Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.
|
|
Academic Article
|
A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer.
|
|
Academic Article
|
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
|
|
Academic Article
|
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study.
|
|
Academic Article
|
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
|
|
Academic Article
|
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
|
|
Academic Article
|
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
|
|
Academic Article
|
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
|
|
Academic Article
|
Oral fluoropyrimidine treatment of colorectal cancer.
|
|
Academic Article
|
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
|
|
Academic Article
|
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
|
|
Academic Article
|
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
|
|
Academic Article
|
Cetuximab in the treatment of colorectal cancer.
|
|
Academic Article
|
3rd EORTC-NCI International Meeting on Cancer Molecular Markers: From Discovery to Clinical Practice.
|
|
Academic Article
|
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue.
|
|
Academic Article
|
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
|
Academic Article
|
First-line treatment options for patients with metastatic colorectal cancer.
|
|
Academic Article
|
Are targeted therapies really targeted?
|
|
Academic Article
|
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
|
|
Academic Article
|
Refocusing the war on cancer: the critical role of personalized treatment.
|
|
Academic Article
|
A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).
|
|
Academic Article
|
Commentary: tackling the challenges of developing targeted therapies for cancer.
|
|
Academic Article
|
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
|
Academic Article
|
Nonmalignant complications of therapy for Hodgkin's disease.
|
|
Academic Article
|
Concomitant 5-FU, hydroxyurea and cisplatin with external beam radiation therapy for locally advanced pancreatic cancer.
|
|
Academic Article
|
Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
|
|
Academic Article
|
Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B.
|
|
Academic Article
|
Tumor heterogeneity as the foundation of personalized cancer treatment.
|
|
Academic Article
|
A randomized study of inpatient versus outpatient continuous intravenous infusion chemotherapy: psychosocial aspects.
|
|
Academic Article
|
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
|
Academic Article
|
Clinical trials in the era of personalized oncology.
|
|
Academic Article
|
Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results.
|
|
Academic Article
|
Infertility in patients with testicular cancer: testis, tumor, or treatment?
|
|
Academic Article
|
Chemotherapy for testicular cancer: current status of the National Cancer Institute Combined Modality Trial.
|
|
Academic Article
|
Molecular markers to individualize adjuvant therapy for colon cancer.
|
|
Academic Article
|
Effects of cancer treatment on the reproductive system.
|
|
Academic Article
|
GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy.
|
|
Academic Article
|
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.
|
|
Academic Article
|
Using patient-initiated study participation in the development of evidence for personalized cancer therapy.
|
|
Academic Article
|
Gonadal dysfunction in patients receiving chemotherapy for cancer.
|
|
Academic Article
|
Targeted therapy for cancer: asking the right questions.
|
|
Academic Article
|
Sequential therapy with dacarbazine and carmustine: a phase I study.
|
|
Academic Article
|
Gonadal and sexual function in male patients with hairy cell leukemia: lack of adverse effects of recombinant alpha 2-interferon treatment.
|
|
Academic Article
|
American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.
|
|
Academic Article
|
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward.
|
|
Academic Article
|
Ovarian function following radiation and chemotherapy for cancer.
|
|
Academic Article
|
MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
|
|
Academic Article
|
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study.
|
|
Academic Article
|
Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
|
|
Academic Article
|
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
|
|
Academic Article
|
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
|
|
Academic Article
|
Phase I study of adozelesin administered by 24-hour continuous intravenous infusion.
|
|
Academic Article
|
Pharmacodynamics in cancer therapy.
|
|
Academic Article
|
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
|
|
Academic Article
|
An accelerated pathway for targeted cancer therapies.
|
|
Academic Article
|
Role of randomized phase III trials in an era of effective targeted therapies.
|
|
Academic Article
|
The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of malignant lymphomas.
|
|
Academic Article
|
Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer.
|
|
Academic Article
|
Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.
|
|
Academic Article
|
Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations.
|
|
Academic Article
|
Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.
|
|
Academic Article
|
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.
|
|
Academic Article
|
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.
|
|
Academic Article
|
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
|
|
Academic Article
|
Precision cancer medicine: the future is now, only better.
|
|
Academic Article
|
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.
|
|
Academic Article
|
Progress against GI cancer during the American Society of Clinical Oncology's first 50 years.
|
|
Academic Article
|
Highlights from the 2016 WIN Symposium, 27-29 June 2016, Paris: personalised therapy beyond next-generation sequencing.
|
|
Academic Article
|
Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis.
|
|
Academic Article
|
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.
|
|
Academic Article
|
Drivers of change in cancer care.
|
|
Academic Article
|
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer.
|
|
Academic Article
|
Response.
|
|
Academic Article
|
Highlights from the 2013 WIN Symposium: personalised cancer therapy from innovation to implementation.
|
|
Academic Article
|
Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine.
|
|
Academic Article
|
Hans Christian Andersen and the Value of New Cancer Treatments.
|
|
Academic Article
|
Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement.
|
|
Academic Article
|
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.
|
|
Academic Article
|
Drug approval challenges in the age of personalized cancer treatment.
|
|
Academic Article
|
Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.
|
|
Academic Article
|
Recommendations for management of patients with neuroendocrine liver metastases.
|
|
Academic Article
|
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.
|
|
Academic Article
|
American Society of Clinical Oncology 2013 top five list in oncology.
|
|
Academic Article
|
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 Summary.
|
|
Academic Article
|
Improving evidence developed from population-level experience with targeted agents.
|
|
Academic Article
|
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.
|
|
Academic Article
|
Modernizing Eligibility Criteria for Molecularly Driven Trials.
|
|
Academic Article
|
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
|
|
Academic Article
|
Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging Expertise.
|
|
Academic Article
|
The promise of Immuno-oncology: implications for defining the value of cancer treatment.
|
|
Academic Article
|
Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies.
|
|
Academic Article
|
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
|
|
Academic Article
|
Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations.
|
|
Academic Article
|
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group.
|
|
Academic Article
|
Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
|
|
Academic Article
|
Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival.
|
|
Academic Article
|
What can heart failure trialists learn from oncology trialists?
|
|
Academic Article
|
Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry.
|
|
Academic Article
|
Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States.
|
|
Academic Article
|
Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies.
|
|
Grant
|
Cancer and Leukemia Group B
|
|
Grant
|
Cancer and Leukemia Group B Human Specimen Repositories
|
|
Grant
|
CANCER AND LEUKEMIA GROUP B--PET COMMITTEE
|
|
Grant
|
CALGB STUDIES OF BREAST CANCER IN THE ELDERLY
|
|
Grant
|
Cancer and Leukemia Group B CCOP Research Base
|
|
Grant
|
CELLULAR PHARMACOLOGY OF THE STEREOISOMERS OF LEUCOVORIN
|
|
Academic Article
|
A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology.
|
|
Academic Article
|
Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer.
|